Key facts
- Rarity Bioscience’s last known valuation is $19.9M.
- It has raised $11.7M; the latest was Early Stage VC ($6.9M) in Jun 2024.
- Notable investors include Joseph Bernardo, Navigare Ventures, Novalis Biotech, STUNS Life Science, UU Invest.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Rarity Bioscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Rarity Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Rarity Bioscience
Developer of molecular amplification technology designed to detect small amounts of DNA sequence variants. The company's platform uses an ultrasensitive multiplex assay for detecting rare nucleic acid sequences in biological samples like liquid biopsies, enabling physicians with technology for research as well as clinical applications.
- Sector
- Healthcare
- HQ
- Uppsala, Sweden
- Founded
- 2021
- Employees
- 23
- Website
- raritybioscience.com/
- Ownership
- Privately Held (backing)
Rarity Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rarity Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rarity Bioscience in its N-PORT filings yet. We sweep new filings monthly.